EDIT – editas medicine, inc. (US:NASDAQ)
Stock Stats
News
11/25
08:02 am
edit
Medium
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Bank of America Co. from a "buy" rating to an "underperform" rating. They now have a $1.00 price target on the stock, down previously from $13.00.
11/6
01:02 pm
edit
Low
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
11/6
09:00 am
edit
Low
Editas Medicine to Participate in Upcoming Investor Conferences
11/6
07:21 am
edit
Medium
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19% [Yahoo! Finance]
11/5
05:34 pm
edit
Medium
Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
11/4/2024
07:30 am
EDIT
-1.4%
BEAT
8/7/2024
07:00 am
EDIT
-10.1%
MISS
5/8/2024
07:00 am
EDIT
-10.1%
MISS
2/28/2024
07:00 am
EDIT
24.5%
BEAT
11/6
01:02 pm
Upgrades
In-line
Outperform
Evercore ISI
Low
-3.0%
11/6
01:02 pm
Upgrades
In-line
Outperform
Evercore ISI
Low
-3.0%
11/5
05:34 pm
Reiterates
Buy
Buy
Chardan Capital
Medium
6.8%
11/5
05:22 pm
Maintains
Buy
Buy
Chardan Capital
Medium
5.1%
11/5
11:32 am
Maintains
Sector Perform
Sector Perform
RBC Capital
Low
-0.8%
11/12
02:30 pm
edit
Neutral
Form SC 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC
11/4
11:57 am
edit
Medium
Form SC 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC
11/4
07:37 am
edit
Low
Form 10-Q Editas Medicine, Inc. For: Sep 30
11/4
07:33 am
edit
Low
Form 8-K Editas Medicine, Inc. For: Nov 04
10/22
07:05 am
edit
High
Form 8-K Editas Medicine, Inc. For: Oct 22
Show more
Top News Gainers
6/7 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%
11/12 Q3/2019 9/30/2019 EPS -0.660 ZacksConsensus -0.730 ActVsEst 0.070 - Beat 6.9%
5/4 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.4%
11/28 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 3.6%
11/13 Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool] 3.7%
10/19 Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth [Yahoo! Finance News] 3.7%
6/14 Form 4 Editas Medicine, Inc. For: Jun 12 Filed by: Hirsch Andrew 4.0%
8/29 Editas Medicine to Participate in Upcoming Investor Conferences 4.5%
3/4 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 5.1%
3/5 Editas Medicine Inc (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock. 5.2%
Top News Decliners
11/26 Better Buy: Editas Medicine or Sangamo Therapeutics? [The Motley Fool] -4.6%
3/20 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.6%
4/30 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update -4.9%
8/27 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.1%
7/30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update -5.8%
2/22 Better Buy: Editas Medicine vs. Intellia [The Motley Fool] -6.2%
2/21 Editas Medicine Inc (NASDAQ: EDIT) is now covered by analysts at Wells Fargo & Co. They set an "equal weight" rating and a $28.00 price target on the stock. -6.7%
2/26 Form S-8 Editas Medicine, Inc. -6.8%
4/1 Better Buy: Editas Medicine vs Sangamo Therapeutics [The Motley Fool] -8.1%
5/10 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3